1.
Light chain amyloidosis is the most common form of systemic amyloidosis and is often associated with plasma cell neoplasms. Clonal or malignant plasma cells produce excess free immunoglobulin light chains, which leads to protein misfolding, aggregation, and multisystem amyloid deposition, most commonly in antiparallel beta‐pleated sheets [1]. Amyloid deposits can be seen in any tissue but are often found in vessel walls, which are particularly susceptible. Over 60% of bone marrow (BM) biopsies in patients with light chain amyloidosis will demonstrate amyloid deposits in vessel walls or stroma [1]; however, deposits in the BM aspirate smear are rare.
A 50‐year‐old male presented with multiorgan imaging abnormalities, biventricular cardiac hypertrophy, and elevated serum lambda light chains (402 mg/L). An endomyocardial biopsy revealed cardiac amyloidosis, with liquid chromatography tandem mass spectrometry (LC/MS) demonstrating AL (lambda)‐type amyloid deposition. A BM biopsy was performed for further workup. Peripheral blood (PB) demonstrated mild normocytic anemia (Hgb 12.2 g/dL) and thrombocytosis (platelets 768 × 109/L). BM aspirate, clot section, and core biopsy showed increased neoplastic plasma cells (∼20%) with cytologic atypia and extensive interstitial and vascular deposition of amorphous material within vessel walls and the interstitium (Figure 1A). Strikingly, these deposits were even visible on the aspirate smear as thick, amorphous, and waxy basophilic globules (Figure 1B). Congo red stains performed on the aspirate smear and core biopsy confirmed these amorphous deposits to be apple‐green birefringent under polarized light (Figure 1C,D). Ancillary studies, including flow cytometric immunophenotyping and cytogenetic/FISH studies confirmed an aberrant monotypic lambda‐restricted plasma cell population demonstrating gains of Chromosomes 3, 7, 11, 15, 18, 19, and 21; Trisomy 9 and 15; and an extra copy of CCND1 (11q13). The constellation of these findings led to a diagnosis of extensive amyloidosis (AL‐lambda type) in the setting of a plasma cell neoplasm. The patient was treated with six cycles of daratumumab, cyclophosphamide, bortezomib, and dexamethasone and underwent autologous stem cell transplant. He is currently on bortezomib maintenance therapy at 35‐month follow‐up, postdiagnosis.
FIGURE 1.
Morphology findings of amyloidosis (AL‐lambda type) in the setting of a plasma cell neoplasm: (A) Bone marrow core biopsy demonstrating extensive interstitial deposition of pink amorphous material (black arrows, hematoxylin and eosin stain, 200× magnification). (B) Bone marrow aspirate smear demonstrating thick, waxy, and amorphous basophilic deposits (black arrows) amid scattered neoplastic plasma cells (blue arrows) (Wright‐Giemsa stain, 500× magnification). (C) Congo red stain on the aspirate smear confirming apple‐green birefringence of amorphous deposits (100× magnification). (D) Congo red stain on the core biopsy confirming apple‐green birefringence of interstitial deposits (200× magnification).
Amyloid deposits in AL‐amyloidosis can be found in any tissue and can lead to organ dysfunction and death, with a major prognostic indicator being the extent of cardiac involvement [1, 2]. In the BM, deposits are usually identified on core biopsy, most commonly within vessel walls, but also in periosteal areas and within the interstitium. Our case demonstrates very striking, extensive involvement by AL‐amyloidosis, with amorphous, and Congo red birefringent amyloid deposits that also visible on aspirate smear. This is a rare and interesting finding with only a few cases reported in the literature [2, 3]. While uncommon, our case highlights the importance of careful review of the aspirate smears, as identification of similar findings can allow a quick diagnosis of amyloidosis if BM biopsy sections are not available.
Author Contributions
A.K. and W.C. contributed to the writing of the manuscript.
Ethics Statement
The authors have nothing to report.
Consent
The authors have nothing to report.
Conflicts of Interest
The authors declare no conflicts of interest.
Funding: The authors received no specific funding for this work.
Clinical Registration: The authors have confirmed clinical trial registration is not needed for this submission.
Data Availability Statement
Data sharing is not applicable to this article as no new data were created or analyzed in this study.
References
- 1. Merlini G., Seldin D. C., and Gertz M. A., “Amyloidosis: Pathogenesis and New Therapeutic Options,” Journal of Clinical Oncology 29, no. 14 (2011): 1924–1933, 10.1200/JCO.2010.32.2271. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Kimmich C., Schönland S., Kräker S., et al., “Amyloid in Bone Marrow Smears in Systemic Light‐Chain Amyloidosis,” Amyloid 24, no. 1 (2017): 52–59, 10.1080/13506129.2017.1314959. [DOI] [PubMed] [Google Scholar]
- 3. Li T. H. S., Wong K. F., and Wong W. S., “Extensive Amyloid Deposits in Bone Marrow Aspirate Smears,” Clinical Case Reports 8, no. 12 (2020): 3581–3582, 10.1002/ccr3.3236. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
Data sharing is not applicable to this article as no new data were created or analyzed in this study.